2025-07-19 - Analysis Report
Okay, here's the analysis of Eli Lilly and Co (LLY) based on the provided data, presented as a report with numerical summaries and accompanying analysis.

**Report: Eli Lilly and Co (LLY) Analysis**

**1. Performance Overview**

*   **Ticker:** LLY
*   **Company Description:** Eli Lilly and Co is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.
*   **Cumulative Return:** LLY's cumulative return is 247.32%, significantly outperforming the S&P 500 (VOO).
*   **S&P 500 (VOO) Cumulative Return:** 96.72%
*   **Spread Analysis (LLY vs. VOO):**
    *   **Current Spread:** 152.3
    *   **Max Spread:** 311.6
    *   **Min Spread:** -27.3
    *   **Relative Spread:** 53.0 (indicating the current spread is in the 53rd percentile of its historical range).

**Analysis:** LLY has demonstrated substantial outperformance compared to the S&P 500. The relative spread indicates that while the current outperformance is significant, it's positioned a little above the median of its historical range, but has plenty of room to grow.

**Alpha, Beta Analysis:**

| Year      | CAGR    | MDD   | Alpha   | Beta   | Cap(B) |
| :---------- | :------ | :------ | :------ | :----- | :------ |
| 2015-2017 | 10.0%   | 56.3% | -19.0%  | 0.0    | 75.8   |
| 2016-2018 | 39.0%   | 58.6% | 21.0%   | -0.1   | 103.9  |
| 2017-2019 | 50.0%   | 58.6% | 20.0%   | 0.3    | 118.0  |
| 2018-2020 | 52.0%   | 58.6% | 33.0%   | 0.1    | 151.6  |
| 2019-2021 | 106.0%  | 60.6% | 57.0%   | 0.2    | 248.0  |
| 2020-2022 | 98.0%   | 64.8% | 96.0%   | 0.2    | 328.4  |
| 2021-2023 | 133.0%  | 64.8% | 115.0%  | 0.3    | 523.3  |
| 2022-2024 | 150.0%  | 72.2% | 124.0%  | 0.2    | 693.0  |
| 2023-2025 | 100.0%  | 76.8% | 52.0%   | 0.2    | 692.8  |

**Analysis:** The table illustrates several key points:

*   **CAGR:**  The Compound Annual Growth Rate has been exceptionally high in recent periods, peaking at 150% (2022-2024).
*   **MDD:** Maximum Drawdown has increased over time. This is typical with growth stocks.
*   **Alpha:**  LLY has consistently generated positive alpha, indicating it has outperformed its benchmark on a risk-adjusted basis. The alpha has been particularly high in recent years, demonstrating significant value added beyond market returns.
*   **Beta:** Beta values are generally low, suggesting that LLY's price is not highly correlated with the overall market (S&P 500). In some periods, it's even negative, indicating a potential tendency to move inversely to the market.
*   **Cap:** Market Cap has grown significantly

**2. Recent Price Action**

*   **Current Price:** 771.71
*   **Previous Close:** 761.5
*   **Price Change:** 1.34%
*   **5-day Moving Average:** 778.82
*   **20-day Moving Average:** 780.634
*   **60-day Moving Average:** 779.96

**Analysis:** The recent price movement shows a slight increase compared to the previous close. However, the current price is below the 5-day, 20-day, and 60-day moving averages, suggesting a short-term downward trend or consolidation phase.

**3. Market Risk Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.3399 (Low Risk)
*   **RSI:** 48.57 (Neutral - Neither overbought nor oversold)
*   **PPO:** -0.2733 (Slightly below zero, indicating potential weakness)
*   **Hybrid Signal:** cash\_0% Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   **Recent (20-day) Relative Spread Change:** -1.0 (Negative, indicating short-term underperformance relative to the S&P 500)
*   **Expected Return:** 143.4% (Projected long-term excess return compared to the S&P 500)

**Analysis:**

*   The Market Risk Indicator suggests a low-risk environment.
*   The RSI is neutral, indicating that the stock is neither overbought nor oversold.
*   The negative PPO indicates potential short-term weakness or a potential buying opportunity if the long-term outlook remains strong.
*   The negative change in relative spread aligns with the price being below moving averages, indicating short-term underperformance.
*    Given that {'price': 771.71, 'previousClose': 761.5, 'change': 1.34} shows that the change is 1.34%, 급반등을 의미합니다.
*   The high expected return suggests that LLY is projected to significantly outperform the S&P 500 over the long term (2+ years).

**4. Recent News & Significant Events**

*   **[2025-07-19]:** Major business developments, regulatory changes, or market events are impacting Eli Lilly and Co.
*   **[2025-07-15]:** Analysts are discussing Eli Lilly and Co's recent performance and outlook.
*   **[2025-07-18]:** Eli Lilly and Co's stock has shown notable volatility.
*   **[2025-07-16]:** Market experts highlight both risks and opportunities for Eli Lilly and Co.

**Analysis:** Recent news indicates significant activity surrounding LLY, including potential business developments, regulatory changes, market events, and analyst discussions. The volatility mentioned suggests that investors should be prepared for price swings. Monitoring these developments is crucial for understanding the current investment landscape.

**5. Recent Earnings Analysis:**

| 날짜       | EPS   | 매출        |
| :--------- | :---- | :---------- |
| 2025-05-01 | 3.07  | 12.73 B$   |
| 2024-10-30 | 1.08  | 11.44 B$   |
| 2024-08-08 | 3.29  | 11.30 B$   |
| 2024-04-30 | 2.49  | 8.77 B$    |
| 2025-05-01 | 2.49  | 8.77 B$    |

**Analysis:**
*   **Revenue Growth:** Overall, there's a general trend of increasing revenue, particularly noticeable in the most recent quarters(2025-05-01)
*   **EPS Volatility:** EPS has fluctuated, but remains strong.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
| :----------- | :-------- | :-------------- |
| 2025-03-31   | $12.73B   | 82.53%          |
| 2024-12-31   | $13.53B   | 82.24%          |
| 2024-09-30   | $11.44B   | 81.02%          |
| 2024-06-30   | $11.30B   | 80.80%          |
| 2024-03-31   | $8.77B    | 80.91%          |

**Capital and Profitability:**

| Quarter      | Equity    | ROE       |
| :----------- | :-------- | :-------- |
| 2025-03-31   | $15.76B   | 17.50%    |
| 2024-12-31   | $14.19B   | 31.07%    |
| 2024-09-30   | $14.24B   | 6.81%     |
| 2024-06-30   | $13.56B   | 21.88%    |
| 2024-03-31   | $12.81B   | 17.51%    |

**Analysis:**

*   **Revenue and Profitability:** Revenue shows a clear upward trend, indicating robust growth. Profit margins are exceptionally high and stable, consistently above 80%. This suggests strong pricing power and efficient cost management.
*   **Capital and Profitability:** Equity has been steadily increasing, reflecting the company's ability to retain earnings and grow its asset base. Return on Equity (ROE) has fluctuated, but is generally strong. The high ROE in 2024-12-31 suggests particularly efficient use of equity to generate profits during that period.

**7. Overall Summary and Recommendation**

Eli Lilly and Co (LLY) exhibits strong fundamentals and growth potential. The company has significantly outperformed the S&P 500, boasts high revenue growth and profit margins, and is expected to continue generating excess returns.

**Key Positives:**

*   Significant outperformance relative to the S&P 500.
*   High and stable profit margins.
*   Positive alpha generation.
*   Strong revenue growth trend.
*   Low Market Risk Indicator.
*   High expected future returns.

**Key Considerations:**

*   Recent short-term price weakness and negative change in relative spread warrant monitoring.
*   Increased MDD(maximum drawndown)
*   Recent news indicates potential volatility.

**Overall:** Considering the strong long-term growth prospects, high profitability, and potential for continued outperformance, LLY appears to be a promising investment. Investors should monitor recent news and price action for any significant developments. The hybrid signal recommends caution, but also suggests a buy.
